https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
First quarter (2022-09-01 until 2022-11-30)
● Operating income amounted to 3 012 (1 347) TSEK, of which Cellaviva counted for 2 137 (1 346) TSEK.
● Operating result amounted to -8 918 (-6 472) TSEK.
● Earnings per share* amounted to -0,26 (-0,19) SEK .
● Cash and bank amounted to 88 259 (133 464) TSEK.
● Solidity** amounted to 92,0 (94,1) %.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the first quarter 2022/2023: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of November 30, 2022: 34,379,523 (34,379,523) shares.
**Solidity: Own capital's share of the sheet total
Significant events in the first quarter
● NextCell announced in early September that the company's CEO Mathias Svahn gives a status update at Nordic Life Science days in Malmö, which is the Nordic region's largest partnering event in Life Science.
● In early October, the company published a debate article on particle in cell and gene therapy products with the International Society for Cell and Gene Therapy's Process Development, Manufacturing and Analytics Committee in the journal Cytotherapy.
● NextCell announced in mid-October that patients with type-1 diabetes that has undergone two treatments with a high dose of ProTrans cell therapy has maintained significantly higher endogenous insulin production than patients treated with low and medium dose.
● At the end of October, NextCell's CEO,
Significant events after the reporting period
● NextCell announced in mid-December that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in phase II part of the paediatric diabetes study.
● The company announced in mid-January that it had received positive comments and recommendations on the proposal for paediatric plan (PIP) previously submitted to the Paediatric Unit of the
● NextCell announced at the end of January that it is expanding the
This disclosure contains information that
For more information about
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Website:
LinkedIn: https://www.linkedin.com/company/15255207/
Certified Adviser
About
https://news.cision.com/nextcell-pharma-ab/r/nextcell-publishes-its-interim-report-1-2022-2023,c3703224
https://mb.cision.com/Main/15834/3703224/1804570.pdf
(c) 2023 Cision. All rights reserved., source